Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?
- AzurRx BioPharma Inc (NASDAQ: AZRX) has announced topline results from its Phase 2 Combination Trial evaluating MS1819 with porcine-derived pancreatic enzyme replacement therapy (PERT) for severe exocrine pancreatic insufficiency in cystic fibrosis (CF) patients.
- Data collected from 20 patients indicated that MS1819 in combination with PERT led to clinically meaningful improvements in the primary efficacy endpoint, the Coefficient of Fat Absorption (CFA).
- Patients showed an average gain of more than six percentage points from baseline, compared to the five-point improvement in CFA cited by the clinical literature.
- The study also demonstrated positive improvements in weight gain and other secondary endpoints.
- Related: AzurRx BioPharma Stock Gains On Positive Interim Data Of MS1819-PERT Combo In Pancreatic Insufficiency.
- From baseline, CFA increased by 6.57%, mean body weight increased by 3.75 pounds, stool weight decreased by 164 grams/day, and the mean daily number of stools decreased by 0.43.
- AzurRx is now developing a new enteric-coated microbead formulation for MS1819 and plans to initiate a bridging study in 2022 evaluating the formulation as a single-agent therapy.
- Formulation work is expected to be completed by the end of 2021.
- MS1819 is a recombinant lipase enzyme.
- Price Action: AZRX shares are up 45.4% at $0.76 during the premarket session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech Long Ideas News Penny Stocks Health Care Movers Trading Ideas General
